MedPath

Fluticasone furoate

Generic Name
Fluticasone furoate
Brand Names
Arnuity Ellipta, Avamys, Breo Ellipta, Flonase Sensimist, Trelegy Ellipta, Veramyst
Drug Type
Small Molecule
Chemical Formula
C27H29F3O6S
CAS Number
397864-44-7
Unique Ingredient Identifier
JS86977WNV
Background

Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications. Fluticasone furoate was first approved in 2007.

Indication

Fluticasone furoate is indicated for once-daily maintenance (i.e. prophylactic) treatment of asthma in patients ≥5 years old. Fluticasone furoate is available in two combination medications - one in combination with vilanterol and one in combination with both vilanterol and umeclidinium- which are both indicated for the management of chronic obstructive pulmonary disease (COPD) and for the treatment of asthma in patients ≥18 years old for the vilanterol-umeclidinium-fluticasone product and ≥5 years old for the vilanterol-fluticasone product.

Fluticasone furoate is available over the counter as a nasal spray for the symptomatic treatment of hay fever and other upper respiratory allergies in patients ≥2 years old.

Associated Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergy, Seasonal Allergies
Clinical Trials
Related News

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Phase 3
Recruiting
Conditions
Asthma
Interventions
Device: ELLIPTA
Drug: FF/VI
First Posted Date
2023-03-07
Last Posted Date
2024-05-28
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
292
Registration Number
NCT05757102
Locations
🇹🇷

GSK Investigational Site, Konyaalti, Turkey

Medical vs Surgical Treatment in OSA Among Children

Phase 4
Conditions
To Determine Clinical Response to Montelukast or Nasal Steroids Based on PSQ Results
To Evaluate PSQ as Clinical Tool in the Decision Between Medical and Surgical Treatment for Adenotonsillar Hypertrophy
Interventions
First Posted Date
2022-12-15
Last Posted Date
2022-12-15
Lead Sponsor
Assaf-Harofeh Medical Center
Target Recruit Count
90
Registration Number
NCT05651750
Locations
🇮🇱

Assaf-Harofeh Medical Center, Be'er Ya'aqov, Israel

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

Phase 4
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2022-09-10
Last Posted Date
2024-11-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
463
Registration Number
NCT05535972
Locations
🇵🇱

GSK Investigational Site, Warszawa, Poland

Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps.

Phase 1
Conditions
Montelukast
Chronic Rhinosinusitis With Nasal Polyps
Interventions
First Posted Date
2021-12-03
Last Posted Date
2022-03-18
Lead Sponsor
Assiut University
Target Recruit Count
60
Registration Number
NCT05143502
Locations
🇪🇬

Assiut University Hospital, Assiut, Egypt

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: FF/VI
Device: ELLIPTA
First Posted Date
2021-06-24
Last Posted Date
2025-01-17
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
359
Registration Number
NCT04937387
Locations
🇨🇳

GSK Investigational Site, Zunyi, China

A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Phase 4
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Device: ELLIPTA
First Posted Date
2021-06-11
Last Posted Date
2025-03-24
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
229
Registration Number
NCT04923347
Locations
🇮🇳

GSK Investigational Site, Pune, India

Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma

Phase 3
Active, not recruiting
Conditions
Asthma
Interventions
First Posted Date
2020-12-03
Last Posted Date
2024-04-03
Lead Sponsor
Dr. Grace Parraga
Target Recruit Count
31
Registration Number
NCT04651777
Locations
🇨🇦

Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre, London, Ontario, Canada

Effect of Fluticasone Furoate on Methacholine Challenge

Phase 4
Completed
Conditions
Asthma
Interventions
Other: Matching placebo
First Posted Date
2019-04-02
Last Posted Date
2019-12-10
Lead Sponsor
University of Saskatchewan
Target Recruit Count
14
Registration Number
NCT03898466
Locations
🇨🇦

Asthma Research Lab University of Saskatchewan Room 346 Ellis Hall, Saskatoon, Saskatchewan, Canada

Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray Irradiation

Not Applicable
Completed
Conditions
Allergic Rhinitis
Interventions
Device: infrared-C ray irradiation
Device: eye mask
First Posted Date
2018-09-17
Last Posted Date
2018-09-17
Lead Sponsor
Nanhua University
Target Recruit Count
50
Registration Number
NCT03673384

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 4
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: budesonide/formoterol
Drug: albuterol/salbutamol
Drug: Placebo to match budesonide/formoterol
Drug: Placebo to match FF/UMEC/VI
Drug: placebo to match tiotropium
Device: ELLIPTA
Device: MDI
Device: HandiHaler
First Posted Date
2018-03-27
Last Posted Date
2020-10-28
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
732
Registration Number
NCT03478696
Locations
🇩🇪

GSK Investigational Site, Leipzig, Germany

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy